Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 2/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21870612 | 0.89 | OPRK1 (0.47) | OPRK1EPHX2EPHX1PIK3CDMAPT | |
| SCHEMBL21290467 | 0.89 | OPRK1 (0.47) | OPRK1EPHX2EPHX1PIK3CDMAPT | |
| SCHEMBL6418827 | 0.85 | OPRK1 (0.49) | OPRK1EPHX2EPHX1SMN1; SMN2 | |
| SCHEMBL21870607 | 0.82 | OPRK1 (0.47) | OPRK1EPHX2EPHX1SMN1; SMN2 | |
| SCHEMBL10938895 | 0.81 | EPHX2 (0.53) | EPHX2EPHX1MAPT | |
| SCHEMBL27322279 | 0.80 | EPHX2 (0.46) | OPRK1EPHX2EPHX1MAPTPRMT5 | |
| SCHEMBL25769752 | 0.80 | CA1 (0.43) | OPRK1EPHX2EPHX1PIK3CDSMN1; SMN2 | |
| SCHEMBL2102575 | 0.79 | EPHX2 (0.51) | EPHX2EPHX1MAPT | |
| SCHEMBL19509462 | 0.79 | EPHX2 (0.51) | EPHX2EPHX1MAPT | |
| SCHEMBL13803920 | 0.79 | EPHX2 (0.51) | EPHX2EPHX1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212155-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212155-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-09-30 | — | — | US | disclosed |
| US-20210053946-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-02-25 | — | — | US | disclosed |
| US-10710986-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| WO-2020025517-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-02-06 | — | — | WO | disclosed |
| US-20190270727-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2019-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212155-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | OPRK1 2358/4885EPHX2 3652/4885EPHX1 2907/4885 |
| US-20210053946-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | OPRK1 2358/4885EPHX2 3652/4885EPHX1 2907/4885 |
| US-10710986-B2 | PD-1/PD-L1 inhibitors | PDCD1, CD274, PDCD1LG2 | OPRK1 2358/4885EPHX2 3652/4885EPHX1 2907/4885 |
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | OPRK1 463/4885EPHX2 2900/4885EPHX1 2207/4885 |
| US-20190270727-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | OPRK1 2358/4885EPHX2 3652/4885EPHX1 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.